baber/WOPTO huggingface dataset:
Patent CA-2550640-A1 (CA)
Inventor: COAKLEY JOSEPH
IPC: A61M5/44
Filed: 2004-12-17
Abstract: A fluid warming and infusion system. According to one embodiment, the fluid warming and infusion system includes a container for storing a fluid to be infused into a patient, a fluid warmer for warming the fluid prior to the fluid being infused into the patient, a tubing for delivering the fluid to the patient after the fluid has been warmed by the fluid warmer, and a patient insertion device (e.g., a needle, or the like), which is connected to a distal end of the tubing, for insertion into the patient. After being warmed by the fluid warmer, the fluid flows through the tubing and is delivered into the patient by the insertion device. The tube includes a substantially thermally insulating component that prevents the warmed fluid from losing a substantial amount of heat as the fluid flows through the tube.
Patent CA-2553460-A1 (CA)
Title: Method and apparatus for restraining tubular members during well servicing
Inventor: SLAGER IRVIN M
IPC: E21B47/00
Filed: 2006-07-19
Abstract: A method for restraining tubular members during well servicing. A first step involves monitoring a velocity of tubular members as they are withdrawn from a well. A  second step involves activating a tubing restrainer when the velocity of the tubular members exceeds a predetermined threshold.
Patent CA-2553856-A1 (CA)
Title: Environmentally friendly, 100% solids, actinic radiation curable coating compositions and coated surfaces and coated articles and coating methods and assemblages thereof
Inventor: RAMSEY SALLY JUDITH WEINE
IPC: C08F2/50
Filed: 2005-02-04
Abstract: Disclosed are environmentally friendly, substantially all solids coating compositions which are curable using ultra violet and visible radiation. In addition, methods, processes, production lines, and factories, incorporating environmentally friendly, ultra violet and visible radiation curable substantially all solids coating compositions, for coating surfaces, or at least a portion of the surfaces, and curing of the coated surface to obtain partially or fully cured coated surfaces are disclosed. Articles of manufacture incorporating fully cured coated surfaces, in particular motor vehicles and motor vehicle parts or accessories, are also disclosed.
Patent CA-2556504-A1 (CA)
Inventor: GARLAND JAMES K
IPC: A61C19/00
Filed: 2005-01-26
Abstract: La présente invention concerne un porte-empreinte dentaire (12) servant à la réalisation de moulages dentaires. Il comporte une paroi de fond rigide (16) et une paroi latérale (17) relativement fine remontant verticalement du pourtour de la paroi de fond (16) de façon à former une cavité, ouverte sur le dessus, convenant à la réception du matériau de moulage. La paroi de fond (16) et la paroi latérale (17) sont réalisées d'un seul tenant en matériau polymère, la paroi latérale (17) étant réunie à la paroi du fond (16) par un élément de liaison membranaire (19) formé d'un seul tenant avec le pourtour de la paroi de fond (16) et le rebord inférieur de la paroi latérale (17). L'élément de liaison (19) est frangible et se casse facilement de façon que la paroi latérale (17) puisse être enlevée par morceaux de la base et jetée après la prise du matériau de moulage dans la cavité formée par la paroi latérale (17).
Patent CA-2558183-A1 (CA)
Title: Use of enhanced water to improve blood sugar management
Inventor: NAITO HARUSUKE
IPC: A61K33/24
Filed: 2005-03-01
Abstract: The subject invention provides a process and apparatus for making "enhanced water" that is uniquely suitable for improving circulation, hydration and insulin usage with diabetics. Thus, in a preferred embodiment, the invention provides methods for the treatment and/or prevention of diabetes as well as the prevention or delay in development of diabetes-related complications, conditions or diseases.
Patent CA-2558884-A1 (CA)
Inventor: FERRARA EVE
IPC: A61K31/59
Filed: 2005-03-18
Abstract: La présente invention concerne une composition pharmaceutique anhydre, associant au moins un principe actif et un agent siliconé comprenant au moins un élastomère organopolysiloxane, ledit principe actif étant sous une forme solubilisée dans ladite composition.
Patent CA-2559755-A1 (CA)
Inventor: ANDERSON SCOTT C
IPC: A23L33/15
Filed: 2004-11-03
Abstract: A dietary supplement and methods for the manufacture and administration of the same are disclosed for the treatment and/or prevention of digestive disorders and digestive tract-related disorders. The dietary supplement of the present invention is orally administrable, and may be compounded either in a solid form, in a paste form, in a granular form, in a powder form, or in a liquid form. The ingredients of the dietary supplement of the present invention when combined provide a synergistic efficacy which greatly exceeds the sum of the efficacies of the individual ingredients, making the dietary supplement highly effective in the treatment and/or prevention of digestive disorders and digestive tract-related disorders.
Patent CA-2562385-A1 (CA)
Title: Identification of the precise amino acid sequence of the epitope recognized by the potent neutralizing human anti-hiv-1 monoclonal antibody igg1b12
Inventor: WARUK JILLIAN L M
IPC: A61K39/00
Filed: 2005-04-11
Abstract: The IgG1b12 human monoclonal antibody binds gp120 strongly, and is the most potent HIV neutralizing antibody known. The exact amino acid sequence of this binding site is not known. We identified the minimal parts of the HIV-1 gp120 (envelope) protein, which IgG1b12 binds to. We did this by quadrupole time of flight (QqTOF) mass spectrometry using epitope excision. Epitope excision allows for determination of conformational epitopes. To do this we bound gp120 to IgG1b12, digested off all unbound portions of gp120, and then ran mass spectrometry of the resulting IgG1b12-gp120 peptide complex. The results allow us to determine the exact amino acid sequence involved in IgG1b12-gp120 interaction.
Patent CA-2563167-A1 (CA)
Title: Use of flibanserin in the treatment of premenstrual and other female sexual disorders
Inventor: PYKE ROBERT
IPC: A61K31/496
Filed: 2005-04-18
Abstract: The invention relates to a method for the treatment of premenstrual and other female sexual disorders comprising the administration of a therpeutically effective amount of flibanserin.
Patent CA-2566733-A1 (CA)
Inventor: LONGCHAMP PIERRE
IPC: E02D29/07
Filed: 2005-05-11
Abstract: The tunnel is built in successive sections by means of a machine M suitable for operating at the surface and in immersion that is displaced in the water on the sub-sea soil, this machine comprising a fluid-tight working space (6) for accommodating the personnel and equipment required for construction, this space having a rearward-facing opening for building and erecting a section at the rear of the machine and the machine comprising in its forward section a ballastable chamber (7) equipped with means (21-23) for preparing and grading the soil in readiness for erection of a section. Application to construction of a tunnel on the bottom of a body of water.
Patent CA-2569484-A1 (CA)
Inventor: REIFF EMILY A
IPC: C07C43/215
Filed: 2005-06-03
Abstract: Processes for preparing entecavir (I) and novel intermediates thereof using carbon-silicon oxidation.
Patent CA-2569663-A1 (CA)
Title: Using multiple pins for redemption through multiple distribution channels
Inventor: CHAKIRIS PHIL M
IPC: G06Q30/00
Filed: 2005-06-10
Abstract: In one exemplary embodiment, a system (100) and method for enabling a customer (4) to redeem a plurality of identifiers (40) for at least one product associated therewith are provided. A database (22) having stored therein the plurality of identifiers (40) associated with the at least one product is established. The plurality of identifiers (40) are collectively but not individually redeemable for the at least one product (30). A representation of each of the plurality of identifiers (40) is distributed, each representation comprising information sufficient to identify only one of the plurality of identifiers (40). A plurality of redemption identifiers is received from a requestor. A request to redeem the plurality of redemption identifiers (40) is received from the requestor. A first authorization result is issued to the requestor in response to the request.
Patent CA-2570053-A1 (CA)
Title: Markers for atherosclerosis
Inventor: BRAY DOROTHY
IPC: G01N33/68
Filed: 2005-06-09
Abstract: A method for the diagnosis, prognosis or identification of a predisposition towards atherosclerosis and the susceptibility to the development of atherosclerotic plaques and/or vascular obstruction is described, the method comprising analysing a sample to determine the percentage frequency of multiple sub-populations of T-lymphocytes and comparing the data obtained against comparative and/or control data.
Patent CA-2570169-A1 (CA)
Title: Azine-carboxamides as anti-cancer agent
Inventor: AQUILA BRIAN
IPC: C07D213/82
Filed: 2005-06-29
Abstract: The invention relates to chemical compounds, of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
Patent CA-2570352-A1 (CA)
Title: Normal radiation device, filter using the same, optically assisted ceramic filter
Inventor: KAWAI CHIHIRO
IPC: A01M29/12
Filed: 2005-05-27
Abstract: There is provided a normal radiation device capable of effectively causing a catalyst reaction even in a contaminated fluid violently absorbing ultraviolet rays which cannot be processed by an external light source or without using an external ultraviolet ray light source such as an ultraviolet lamp and an ultraviolet LED. Furthermore, there is provided a ceramic filter which can easily be manufactured at a low cost and includes an optical catalyst capable of dissolving organic objects or sterilizing bacteria and virus. A normal radiation device includes a normal radiation body having a function for emitting visible ray or ultraviolet ray by electro-luminescence, wherein a plurality of through holes are formed in the vertical direction with respect to the plane of the normal radiation body so as to serve as a fluid flow path.  Moreover, an optically assisted ceramic filter includes a ceramic filter having a plurality of flow paths and an optical catalyst layer and a normal radiation body which are arranged at the side surface of the ceramic filter.
Patent CA-2571397-A1 (CA)
Title: 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
Inventor: ZHENG CHANGSHENG
IPC: C07D405/14
Filed: 2005-06-27
Abstract: The present invention is directed to compounds of Formula (I) : which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity.
Patent CA-2573836-A1 (CA)
Title: Systems and methods for sorting, collecting data pertaining to and certifying recyclables at a material recovery facility
Inventor: BOHLIG JAMES W
IPC: B03B9/06
Filed: 2005-07-12
Abstract: Systems and methods for collecting data pertaining to glass, plastic and/or paper composition within an input stream that includes recyclable material.  The data collected can pertain, for example, to the weight and/or volume of the glass, plastic and/or paper within the input stream. The data can be certified for use a third party.
Patent CA-2574810-A1 (CA)
Inventor: USCHOLD ROBERT
IPC: A61B5/151
Filed: 2007-01-19
Abstract: A lancing device includes a housing, a moveable lancet holder configured to hold a lancet, and a launching mechanism. The launching mechanism includes a launch spring and retraction spring, at least one of which has been at least partially coated with a dampening material that aids in dampening sound and/or vibration during lancing. In addition, the moveable lancet holder and launching mechanism are operatively connected to lance a target site with the lancet.
Patent CA-2575103-A1 (CA)
Inventor: DOUGLAS JEANNE
IPC: A61B5/00
Filed: 2005-06-22
Abstract: This invention includes a highly torqueable, pushable guidewire with a relatively stiff proximal (preferably in one embodiment), stainless steel (SS) section and kink resistant nitinol medial to distal section attached to a shapeable SS, in one embodiment, (such as a SS ribbon) distal tip. The very distal SS tip will have the ability to be shaped by the end user in order to facilitate entry into the chosen vessels.
Patent CA-2575122-A1 (CA)
Title: Stabilisation d'un procede d'hydroformylation
Inventor: PETERSON RONALD R
IPC: C07C45/50
Filed: 2005-07-19
Abstract: La présente invention a trait à un procédé d'hydroformylation présentant une stabilité améliorée comprenant la réaction d'un ou de plusieurs réactifs, tels qu'une oléfine, avec du monoxyde de carbone et de l'hydrogène en présence d'un catalyseur d'hydroformylation, en vue de produire un fluide de produit réactionnel comportant un ou des produits, de préférence des aldéhydes. Ledit procédé est effectué dans une région de courbe de taux d'hydroformylation qui est négative ou en ordre inversé en monoxyde de carbone; et dans lequel la pression totale est contrôlée à une valeur cible prédéterminée et/ou le débit de ventilation est contrôlé à une valeur cible prédéterminée, par l'ajustement d'un débit de gaz d'admission contenant du monoxyde de carbone, en vue d'empêcher des modifications brusques et/ou de réduire la succession de cycles des paramètre du procédé, par exemple, le taux de réaction, la pression totale, le débit de ventilation, la température, ou une combinaison de ceux-ci.
Patent CA-2577135-A1 (CA)
Title: Deuterium depleted water (ddw) using as adjuvant in cancer therapy for cytostatics toxicity reduction
Inventor: COMISEL VIRGILIU
IPC: A61P35/00
Filed: 2005-07-26
Abstract: The hereby invention addresses to a new application of Deuterium Depleted Water (DDW), namely, its administering, on a concentration of 60 ppm, as daily diet, to adult healthy outbred Wistar rats produces a distinguished lowering of toxic effects produced by cytostatics (Cyclophosphamide, 5-Flourouracil, Farmarubicine and Vinblastine) when they used in these animals mono-chemotherapy. Also, the 60 ppm DDW administering under similar conditions generates a significant cytostatics toxicity (Cyclophosphamide, 5-Flourouracil, Farmarubicine and Vinblastine) used in polychimiotherapy on pet dogs having different types of cancer. These relevant findings confirm the idea of 60 ppm DDW as a new and efficient adjuvant in cancer chemotherapy on pets and humans.
Patent CA-2579179-A1 (CA)
Inventor: MAGES ENGELBERT
IPC: A63B69/32
Filed: 2005-09-15
Abstract: Disclosed is an impact power measuring device (4) comprising several measuring chambers (24) which are provided in an elastic material (24) and are disposed and configured such that an impact that is to be measured and hits at least one of the measuring chambers (24) modifies the volume thereof. Said device (4) further comprises a discharge tube (8) that is connected to the measuring chambers (24) and a sensor (12) which is positioned in said discharge tube (8). The inventive impact power measuring device (4) is characterized in that additional chambers (30) are provided which are not connected to the discharge tube (8) encompassing the sensor (12).
Patent CA-2585015-A1 (CA)
Inventor: BLANCHARD RAYMOND A JR
IPC: B41L21/12
Filed: 2007-04-17
Abstract: A decurler system for tag webs used for example in printers and stackers to automatically remove curl from tag webs to promote further tag handling and better tag appearance. The decurler system may determine the current diameter of a stock roll and gradually adjust parameters such as resistance and back bend so as to compensate for increased set in tag webs as the diameter of the stock roll decreases. In an embodiment, the decurler system may include different sets of parameters for different stock roll diameters depending on the material used for the tag webs.
Patent CA-2588933-A1 (CA)
Inventor: SCHACHT BENNY
IPC: E04F19/06
Filed: 2005-12-22
Abstract: Finishing profile for a floor covering, said profile at least consisting of a body formed by several portions (7-11-52), whereby two or more of these portions can be mutually separated or combined in function of the intended application, characterized in that the body is at least partially encased by means of a layer-shaped covering (46) which, in the non-separated condition or combined condition of at least two of said portions, extends or can extend at least over the transition between these portions.
Patent CA-2589368-A1 (CA)
Title: Nutrition bar
Inventor: GAUTAM AKHILESH
IPC: A23L33/00
Filed: 2005-11-28
Abstract: A nutrition or other food bar which includes, preferably in moderate to high levels, peptides in the form of hydrated high water activity peptides. The peptides are typically either intact proteins or hydrolyzed proteins.  Inclusion of peptides in the form of high water activity peptides helps prevent migration of water from sugars to the proteins which would otherwise result in formation of hard crystalline sugars and food bars which are excessively hard. Whey protein isolate and hydrolyzed whey protein are preferred high water activity peptides.
Patent CA-2589830-A1 (CA)
Title: Ubiquitin ligase inhibitors
Inventor: GURURAJA TARIKERE
IPC: A61P35/00
Filed: 2006-01-05
Abstract: This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination.  Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of MDM2.
Patent CA-2591718-A1 (CA)
Inventor: MAURELLO JOHN
IPC: A47K13/00
Filed: 2007-06-15
Abstract: The present application is directed to an adjustable seat having a hard, firm surface designed to treat hemorrhoids. The hard, firm surface of the seat is designed to place positive pressure on the area surrounding a hemorrhoid so as to develop a negative pressure within the body which causes the body to draw the hemorrhoids back up into the body. Many seats on the market today for hemorrhoids are designed simply to alleviate the symptoms that are associated with hemorrhoids and not treat the condition.  In contrast to the seat of the present invention, these seats are usually soft cushioned seats designed to support hemorrhoids that protrudes from the anus or the surrounding area so as to reduce discomfort.
Patent CA-2598846-A1 (CA)
Inventor: BEUTLER ULRICH
IPC: C07C211/30
Filed: 2006-02-23
Abstract: Process for the purification from non-metal contaminants of the allylamine pharmaceutical terbinafine of formula (I) in free base form or acid addition salt form, by distilling crude terbinafine base, preferably by short path distillation, e.g. at a temperature above 100~C and reduced pressure, e.g. 0.2 mbar (method A), optionally together with salt formation of the resultant product under simultaneous precipitation of pure trans isomer (method B), and recovering the pure product in free base or acid addition salt form. Detection of non-metal contaminants such as substance A of formula (II) is preferably effected by RP HPLC analysis with UV detection.
Patent CA-2600525-A1 (CA)
Inventor: MEYER JOANNE
IPC: A61K9/20
Filed: 2006-03-20
Abstract: A retrospective pharmacogenetic analysis was conducted in an attempt to evaluate potential association between genetic variation and outcome of a clinical trial of efficacy of aliskiren as an antihypertensive agent. Forty-eight polymorphisms were examined in twelve genes from the renin-angiotensin-aldosterone system (RAS) or previously implicated in blood pressure regulation. Significant associations were seen between one polymorphism in the angiotensin converting enzyme (ACE) gene, two polymorphisms in the angiotensin II type 2 receptor (AGTR2) gene, and clinical parameters of mean sitting diastolic and systolic blood pressure decrease. These effects were not found with irbesartan and placebo treatment, but instead were specific to aliskiren treatment.
Patent CA-2601044-A1 (CA)
Inventor: KULAKOFSKY DAVID S
IPC: C04B28/06
Filed: 2006-02-03
Abstract: Compositions for performing cementing operations in a subterranean zone under high temperature conditions have a density of less than about 10.5 pounds per gallon, and include calcium aluminate, water, and a lightweight additive having a specific gravity of less than about 0.70.
Patent CA-2601879-A1 (CA)
Title: Methods and apparatus for using audience member behavior information to determine compliance with audience measurement system usage requirements
Inventor: MEARS PAUL
IPC: G06F17/40
Filed: 2006-03-17
Abstract: Example methods, apparatus, and articles of manufacture determine compliance with usage guidelines of an audience measurement system. Initially, location information associated with an audience member is obtained. It is then determined whether the audience member is in compliance with the usage guidelines based on the location information. Media monitoring information corresponding to the location information is then tagged as non-compliant if the audience member is not in compliance with the usage guidelines.
Patent CA-2602075-A1 (CA)
Title: N-alkylcarbonyl-amino acid ester and n-alkylcarbonyl-amino lactone compounds and their use
Inventor: WEI EDWARD TAK
IPC: C07C233/63
Filed: 2006-03-23
Abstract: The present invention generally relates to refreshing, soothing, and cooling compounds that affect sensory processes. More particularly, the present invention pertains to certain N-alkylcarbonyl-amino acid ester and N-alkylcarbonyl-amino lactone compounds as described herein; compositions and articles comprising such compounds; and methods of treatment, for example, methods of alleviating the discomforts of irritation, itch, and pain in the skin and in the linings of the oral cavity and upper respiratory tract, for example, in methods of treatment of cough and/or asthma.
Patent CA-2602178-A1 (CA)
Title: Method, system, access terminal and access network for transmitting forward traffic channel at fixed rate
Inventor: LIU JUEJUN
IPC: H04B7/26
Filed: 2006-08-07
Abstract: A method, a system, an access terminal and an access network for transmitting the forward traffic channel at a fixed rate, which include: when the access terminal determines that it needs receiving the forward traffic channel at a fixed rate from one or several designated specific forward carrier link, it transmits the identification information of specific forward carrier link to the access network, the access network transmits the forward traffic channel at a fixed rate according to the received identification information of specific forward carrier link. The access terminal in present invention can receive the forward traffic channel at a fixed data rate from a forward carrier link in a specified sector, and satisfies the demand that the access terminal needs receiving forward traffic channel at fixed data rate from one or several forward carrier link in the designated specific sector, thereby increases the flexibility of forward traffic channel transmission, perfects the technology of multicarrier EV - DO.